TY - JOUR
T1 - Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study
AU - Iovino, Claudio
AU - Au, Adrian
AU - Chhablani, Jay
AU - Parameswarappa, Deepika C.
AU - Rasheed, Mohammed Abdul
AU - Cennamo, Gilda
AU - Cennamo, Giovanni
AU - Montorio, Daniela
AU - Ho, Allen C.
AU - Xu, David
AU - Querques, Giuseppe
AU - Borrelli, Enrico
AU - Sacconi, Riccardo
AU - Pichi, Francesco
AU - Woodstock, Elizabeth
AU - Sadda, Srinivas R.
AU - Corradetti, Giulia
AU - Boon, Camiel J. F.
AU - van Dijk, Elon H. C.
AU - Loewenstein, Anat
AU - Zur, Dinah
AU - Yoshimi, Sugiura
AU - Freund, K. Bailey
AU - Peiretti, Enrico
AU - Sarraf, David
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Purpose: To study the early anatomic choroidal alterations in eyes with chronic central serous chorioretinopathy (CSCR) undergoing photodynamic therapy (PDT). Design: Multicenter retrospective cohort study. Methods: A total of 77 patients and 81 eyes with chronic CSCR treated with PDT and 64 untreated fellow eyes were evaluated. Central macular thickness (CMT) and choroidal features including subfoveal choroidal thickness (SFCT), total choroidal area (TCA), luminal choroidal area (LCA), and stromal choroidal area (SCA) were analyzed. Choroidal vascularity index (CVI) was calculated in all study eyes at baseline and at 1- and 3-months post-PDT. Results: In eyes receiving PDT, Snellen visual acuity (VA) significantly improved at months 1 and 3 (P <.001). CMT and SFCT showed a significant reduction from baseline at months 1 and 3 (P <.001), whereas TCA and LCA showed a significant decrease only at the 1-month follow-up visit. Baseline mean TCA and LCA were 2.30 ± 1.41 mm 2 and 1.23 ± 0.73 mm 2, respectively, and decreased to 2.07 ± 1.21 mm 2 and 1.08 ± 0.63 mm 2 at the 1-month follow-up visit, respectively (P =.01). No significant changes were recorded for SCA and CVI. In the fellow eye group, VA, CMT, and all choroidal parameters showed no differences between baseline and any follow-up visits (all P >.05). Conclusions: After PDT for chronic CSCR we observed sustained reductions in CMT and SFCT, while reductions in TCA and LCA were only noted at the 1-month follow-up interval. These choroidal parameters may provide additional quantitative biomarkers to evaluate the anatomic response to therapy but await further prospective validation.
AB - Purpose: To study the early anatomic choroidal alterations in eyes with chronic central serous chorioretinopathy (CSCR) undergoing photodynamic therapy (PDT). Design: Multicenter retrospective cohort study. Methods: A total of 77 patients and 81 eyes with chronic CSCR treated with PDT and 64 untreated fellow eyes were evaluated. Central macular thickness (CMT) and choroidal features including subfoveal choroidal thickness (SFCT), total choroidal area (TCA), luminal choroidal area (LCA), and stromal choroidal area (SCA) were analyzed. Choroidal vascularity index (CVI) was calculated in all study eyes at baseline and at 1- and 3-months post-PDT. Results: In eyes receiving PDT, Snellen visual acuity (VA) significantly improved at months 1 and 3 (P <.001). CMT and SFCT showed a significant reduction from baseline at months 1 and 3 (P <.001), whereas TCA and LCA showed a significant decrease only at the 1-month follow-up visit. Baseline mean TCA and LCA were 2.30 ± 1.41 mm 2 and 1.23 ± 0.73 mm 2, respectively, and decreased to 2.07 ± 1.21 mm 2 and 1.08 ± 0.63 mm 2 at the 1-month follow-up visit, respectively (P =.01). No significant changes were recorded for SCA and CVI. In the fellow eye group, VA, CMT, and all choroidal parameters showed no differences between baseline and any follow-up visits (all P >.05). Conclusions: After PDT for chronic CSCR we observed sustained reductions in CMT and SFCT, while reductions in TCA and LCA were only noted at the 1-month follow-up interval. These choroidal parameters may provide additional quantitative biomarkers to evaluate the anatomic response to therapy but await further prospective validation.
UR - http://www.scopus.com/inward/record.url?scp=85086473866&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ajo.2020.04.022
DO - https://doi.org/10.1016/j.ajo.2020.04.022
M3 - Article
C2 - 32360342
SN - 0002-9394
VL - 217
SP - 104
EP - 113
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -